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Abstract
 
Cytomegaloviruses (CMVs) code for several proteins that inhibit the presentation of antigenic
peptides to CD8 T cells. Although the molecular mechanisms of CMV interference with the
major histocompatibility complex class I pathway are long understood, surprisingly little evidence
exists to support a role in vivo. Here we document the first example of the presentation of an
antigenic peptide being blocked by a CMV immune evasion protein in organs relevant to
CMV disease. Although this D
 
b
 
-restricted peptide, which is derived from the antiapoptotic
protein M45 of murine CMV (mCMV), is classified as an immunodominant peptide based on
response magnitude and long-term memory, adoptive transfer of M45 epitope-specific CD8 T
cells did not protect against infection with wild-type mCMV. Notably, the same cells protected
C57BL/6 mice infected with an mCMV mutant in which immune evasion protein m152/gp40
is deleted. These data indicate that direct presentation or cross-presentation of an antigenic peptide
by professional antigen-presenting cells can efficiently prime CD8 T cells that fail in protection
against CMV organ disease because m152/gp40 prevents presentation of this peptide in patho-
genetically relevant tissue cells.
Key words: immunodominance • immune evasion • immune control •
antigen presentation • cross-priming
 
Introduction
 
Viruses encode many potentially antigenic peptides, but
only a few are actually involved in the antiviral immune
response in any given MHC haplotype, a phenomenon
known as immunodominance. Understanding the principles
of how certain peptides are selected to participate in host
defense is of importance for vaccine design (1). CMVs add
a further dimension of complexity to the presentation of
peptides in that they code for specialized immune evasion
proteins, referred to as “immunoevasins” (2) or “viral proteins
interfering with antigen presentation” (3). A set of these
proteins is committed to inhibit the MHC class I–restricted
presentation of peptides to CD8 T cells. In murine CMV
(mCMV) infection, three immunoevasins are operative at
different stages of the MHC class I pathway and cooperate
in diminishing the display of peptides at the cell surface:
m152/gp40 retains peptide-loaded MHC class I complexes
in a cis-Golgi compartment, m06/gp48 reroutes the com-
plexes for lysosomal degradation, and m04/gp34 escorts
MHC class I molecules to the cell surface but precludes
recognition (for review see reference 2).
Yet, these mechanisms in concert do not eventually prevent
the immune surveillance of CMVs by CD8 T cells in the
infected host. Contrary to the consciousness of many, to
date there exists no example of a CMV peptide for which
presentation in vivo is prevented by immunoevasins. Instead,
in the BALB/c model, mCMV-primed polyclonal CD8 T
cells as well as CTL lines (CTLL) specific for five different
epitopes protected against CMV disease in immunocom-
promised adoptive transfer recipients (for review see refer-
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ence 2). Thus, in principle, peptide presentation in vivo
can occur in productively infected tissue cells despite the
expression of immunoevasins.
For the C57BL/6 model, an immunodominant D
 
b
 
-
restricted antigenic peptide with the sequence 985-HGIR-
NASFI-993 has been identified (4) in the antiapoptotic E
phase protein M45 (5). We show here that fully functional
M45 epitope-specific CD8 T cells, propagated as a CTLL
or sorted ex vivo, fail to resolve an in vivo infection by
WT mCMV (mCMV-WT). To the best of our knowl-
edge, efficient priming of a CD8 T cell response to an anti-
genic peptide for which the presentation in productively
infected tissue cells is actively prevented by a viral gene
function is unprecedented and represents a subtle new trick
of a virus to subvert immune control.
 
Materials and Methods
 
Viruses
 
Bacterial artificial chromosome–derived mCMV MW97.01 (6,
7) is here referred to as mCMV-WT. Based on MW97.01, mu-
tants mCMV-
 
 
 
m152 and mCMV-
 
 
 
m04
 
 
 
06
 
 
 
152 have been
generated (8). For the construction of revertant virus mCMV-
 
 
 
m152-rev, gene 
 
m152
 
 was reinserted into the native site in
mCMV-
 
 
 
m152. This was achieved essentially as previously de-
scribed (8) by homologous recombination in 
 
Escherichia coli
 
 be-
tween bacterial artificial chromosome p-
 
 
 
m152 and a linear
PCR fragment containing the 
 
m152
 
 open reading frame flanked
upstream and downstream by 400-bp sequences. Progeny virus
mCMV-
 
 
 
m152-rev was reconstituted by transfection of the re-
vertant genome into mouse embryo fibroblasts (MEFs) as previ-
ously described (7).
 
Infection and Adoptive Cell Transfer
 
For priming, intraplantar infection of immunocompetent
C57BL/6 mice was performed with 10
 
5 
 
PFU mCMV-WT (9).
For adoptive transfer experiments, C57BL/6 recipients were im-
munocompromised by 7.5 Gy 
 
  
 
irradiation. M45-specific CD8 T
cells were transferred i.v. 24 h later, followed by intraplantar in-
fection with 10
 
5 
 
PFU mCMV-WT or mutants. Animal experi-
ments were approved by the Ethics Commission, permission
number 177-07/021-28.
 
Effector Cells
 
Acutely sensitized lymphocytes were isolated at day 8 from
pooled draining popliteal LNs (PLNs). Memory cells were de-
rived after resolution of productive infection from spleens of la-
tently infected mice. 
 
Immunomagnetic Cell Sorting.
 
For subsequent cytofluorimetric
cell sorting, CD8 T cells were enriched by one round of positive
immunomagnetic cell sorting using the autoMACS system
(Miltenyi Biotec). For ELISPOT assays, two sequential runs were
performed to reach 
 
 
 
95% purity. Separation programs Possel™
and Posseld™ (Miltenyi Biotec) were used for one and two col-
umn separation, respectively.
 
Cytofluorimetric Cell Sorting.
 
For the purification of M45
epitope-specific memory cells, preenriched CD8 T cells were la-
beled with FITC-conjugated anti-CD8a mAb (clone 53-6.7, cat-
alog no. 553031; BD Biosciences) and M45 peptide-loaded
Dimer X I H-2D
 
b
 
:Ig (catalog no. 551323; BD Biosciences) with
 
PE-conjugated rat mAb anti–mouse IgG1 (clone A85-1, catalog.
no. 550083; BD Biosciences) as second antibody. EPICS AL-
TRA HyperSort (Beckman Coulter) was operated with EXPO32
acquisition and analysis software. Sort gates were set on living
cells with highly positive FL-1 (FITC) and FL-2 (PE) fluores-
cence, discarding cells with low and intermediate expression.
Sorting was performed in ALTRASort mode 3 with a flow rate
of 
 
 
 
5,000 cells/s.
 
Generation of Peptide-specific CTLL and Cytolytic Assay.
 
Cell
line M45-CTLL was generated by repetitive restimulation of
memory spleen cells (10) at an M45 peptide concentration of
10
 
 
 
10 
 
M. Cytolytic activity was measured in a standard 
 
51
 
Cr release
assay using C57BL/6-derived EL4 thymoma cells as target cells.
 
ELISPOT Assays
 
IFN-
 
 
 
–based ELISPOT assays were performed as previously
described (10), with graded effector cell numbers and triplicate
cultures per titration step. In the CD3
 
 
 
-redirected ELISPOT as-
say (10), cells were polyclonally stimulated via the CD3
 
  
 
mole-
cule by using anti-CD3
 
  
 
mAb-producing hybridoma 145-2C11.
M45 peptide-presenting cells were EL4 pulsed with an optimal
dose (10
 
 
 
8 
 
M) of synthetic M45 peptide. C57BL/6 MEFs were
either left uninfected for control or were infected with mCMV-
WT, mCMV-
 
 
 
m152, or mCMV-
 
 
 
m04
 
 
 
06
 
 
 
152 at a multi-
plicity of infection of 4 PFU/cell (9). Cells were harvested at 1 h
Figure 1. M45 is a dominant antigen. Immunocompetent C57BL/6
mice were infected with mCMV-WT. (A) The acute immune response
in the draining PLN was measured on day 8. (B) Immunological memory
in the spleen was measured at 3 mo. The recognition of target cells by
purified CD8 T cells was tested in the ELISPOT assay. The total response
was determined by polyclonal stimulation via CD3 . The M45 peptide-
specific response was determined by stimulation with EL4 thymoma cells
pulsed with 10 8 M synthetic M45 peptide. C57BL/6 MEFs were used
either uninfected or after infection with the indicated viruses. Frequencies
are given as numbers of IFN- –secreting cells (left) as well as in percent of
all CD8 T cells (right). Bars represent most probable numbers determined by
linear regression analysis. The upper 95% confidence limits are indicated.
P-values for random, nonlinear distribution were  0.001 throughout. 
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after infection and they continued viral gene expression through-
out the assay period. Frequencies of IFN-
 
 
 
–secreting, spot-forming
cells were calculated by intercept-free linear regression analysis
using Mathematica V4.2.1 Statistics software (“LinearRegres-
sion”; Wolfram Research Inc.).
 
Quantitation of Infection in Host Organs
 
Infectious virus was quantitated in organ homogenates by a vi-
rus plaque assay on MEFs (9). The number of infected cells in tis-
sue sections of host organs was determined by IE1 protein-specific
immunohistology or by gene-specific DNA-DNA two-color in
situ hybridization (2C-ISH) (9).
 
Results
 
Immunodominance of M45 in Acute Response and Memory.
 
The numerical participation of M45 epitope-specific CD8
T cells in the immune response of C57BL/6 mice to
mCMV was measured in the draining PLNs at day 8 after
infection, representing the acute primary immune re-
sponse, as well as in the spleen after resolution of produc-
tive infection, representing immunological memory during
viral latency (Fig. 1).
In the acute response (Fig. 1 A), 1.4% of all CD8 T cells
responded to polyclonal signaling via CD3
 
  
 
and 0.3% of all
CD8 T cells, which is 
 
 
 
20% of the CD3
 
 
 
-responsive cells,
were specific for the M45 peptide. Fibroblasts infected with
mCMV-WT were not recognized. This implies that im-
munoevasins affect the presentation of all H-2
 
b
 
–restricted
mCMV peptides, not just of the M45 peptide, in this cell
type. Accordingly, antigenic peptides are presented in
fibroblasts infected with mutants mCMV-
 
 
 
m152 and
mCMV-
 
 
 
m04
 
 
 
06
 
 
 
152 (8), which led to the recognition
by 0.6 and 1% of all CD8 T cells, respectively. The overall
pattern was similar for the memory cells (Fig. 1 B), except
that M45-specific cells were somewhat enriched relative to
the declined numbers of the CD3
 
 
 
-responsive and the total
virus-specific cells.
 
M45-specific Effector Cells Fail to Control In Vivo Infection.
 
The T cell line M45-CTLL was generated by repetitive
restimulation of spleen-derived memory cells with M45
peptide. After the fifth round of stimulation, M45-specific
cytolytic activity (Fig. 2 A) and induction of IFN-
 
  
 
secre-
tion (Fig. 2 B) were tested. Half-maximal lysis was ob-
served with target cells pulsed with M45 peptide at a con-
centration of 10
 
 
 
12 
 
M (Fig. 2 A), which indicates an
affinity that is 
 
 
 
100-fold higher than that of the in vivo
protective IE1-CTLL and m164-CTLL specific for the
two immunodominant mCMV peptides in the H-2
 
d 
 
hap-
lotype (11). A high and comparable proportion of the cells
secreted IFN-
 
  
 
after CD3
 
 
 
-mediated signaling and after
stimulation with the cognate peptide, which indicates
monospecificity (Fig. 2 B). Despite the high sensitivity of
M45-CTLs, fibroblasts infected with mCMV-WT were
not recognized. In contrast, peptide presentation occurred
Figure 2. M45 peptide is only presented in cells infected with immune
evasion gene deletion mutants. An M45 epitope-specific, polyclonal CTLL
was derived from mCMV-WT–infected C57BL/6 mice. (A) Cytolytic
effector function and affinity of M45-CTLL. EL4 target cells were pulsed
with the indicated molar concentrations of M45 peptide. Lysis of target
cells was measured at an E/T ratio of 15. Dot symbols represent mean
values of triplicate assay cultures. (B) Presentation of M45 peptide measured
by the number of M45-CTLs that respond in the ELISPOT assay. For
stimulator cells and statistical analysis, see the legend of Fig. 1.
Figure 3. M45-CTLs fail to control in vivo infection with mCMV-
WT but resolve infection with mutant mCMV- m152. Immunocom-
promised C57BL/6 mice were infected (A) with mCMV-WT or (B)
mCMV- m152. The in vivo antiviral function of M45-CTLs was tested
by adoptive transfer.  , no cell transfer. Virus replication in organs was
measured on day 12. For spleen and lung (left), virus titers were deter-
mined in organ homogenates by a virus plaque assay. The dotted line
indicates the detection level. For the liver, the number of infected hepa-
tocytes was determined by immunohistology specific for the intranuclear
IE1 protein. Dot symbols represent data for individually numbered transfer
recipients. Median values are marked. 
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in fibroblasts infected with the mutant viruses mCMV-
 
 
 
m152 and mCMV-
 
 
 
m04
 
 
 
06
 
 
 
152, but did not engage
all M45-specific cells. This finding shows that stimulation
with infected fibroblasts, even after deletion of the three
immunoevasins, underestimates the number of epitope-
specific effector cells.
These in vitro highly functional M45-CTLs were then
tested for their antiviral in vivo efficacy by adoptive transfer
into immunocompromised C57BL/6 mice infected with
mCMV-WT (Fig. 3 A). Notably, the transferred cells were
completely ineffectual in controlling virus replication in
spleen, lung, and liver.
 
Immunoevasin Deletion Restores the Function of M45-CTLs.
 
Although M45-CTLs were functional in terms of cytolytic
activity and IFN-
 
  
 
secretion, unknown deficiencies in
other parameters could possibly account for their failure in
controlling the in vivo infection. Therefore, we tested
whether M45-CTLs control virus replication in recipients
infected with mCMV-
 
 
 
m152 (Fig. 3 B). Although 10
 
6 
 
of
these cells were ineffectual in controlling mCMV-WT
(Fig. 3 A), as few as 10
 
4 
 
cells significantly reduced the repli-
cation of the mutant virus and 10
 
6 
 
cells almost resolved the
infection in all organs tested.
For ultimate proof, immunocompromised recipients
were coinfected with mutant virus mCMV-
 
 
 
m152 and re-
vertant virus mCMV-
 
 
 
m152-rev (Fig. 4). Gene probes
specific for a shared gene, namely 
 
M55
 
 (gB), and for gene
 
m152
 
 (Fig. 4 A) allowed for a visual discrimination be-
tween cells infected with the mutant (clean red staining)
and cells infected with the revertant (mixed red and black
staining) in the same tissue sections by 2C-ISH. The two
viruses were subjected to an increasing selective pressure
exerted by increasing doses of M45-CTLs, and control of
infection in the liver was determined by counting the
numbers of infected hepatocytes (Fig. 4, B–D). The num-
ber of red-stained hepatocytes infected with mCMV-
 
 
 
m152 declined with increasing selective pressure, whereas
the number of black-stained hepatocytes infected with
mCMV-
 
 
 
m152-rev was not significantly reduced. In con-
clusion, the failure of M45-CTLs to control infection with
mCMV-WT or mCMV-
 
 
 
m152-rev was not caused by a
functional deficiency of the effector cells but by an immu-
noevasin-mediated “invisibility” of infected tissue cells.
 
Nonprotective Memory.
 
Although the data have shown
so far that M45-CTLs fail to control productive infection
with mCMV-WT, M45-specific memory cells are main-
Figure 4. Increasing selective force
by M45-CTLs leads to preferential
loss of mutant virus in coinfected
recipients. Immunocompromised
C57BL/6 mice were infected with a
mixture of viruses mCMV- m152
and mCMV- m152-rev, 105  PFU
each. A selective force was exerted
by adoptive transfer of increasing
numbers of M45-CTLs.  , no cell
transfer. On day 12, virus replication
in the liver was compared by quanti-
tation of infected cells using 2C-ISH.
(A) Maps (not drawn to scale) illus-
trate the design of DNA probes for
discriminating between mCMV-
 m152 (clean red staining) and
mCMV- m152-rev (mixed black
and red staining). (B) Comparative
quantitation of hepatocytes infected
with either of the two viruses. Dot
symbols represent data for individually
numbered transfer recipients. Median
values are marked. (C) 2C-ISH–
stained and hematoxylin counter-
stained liver section of individual
mouse number 1* (no cell transfer),
showing separate red and black foci
of infection. Arrows in the middle
panel point to areas resolved to
greater detail in the flanking higher
resolution images. Note the stained
inclusion bodies, which represent
the site of viral DNA packaging in
the nuclei of infected hepatocytes.
(D) 2C-ISH–stained and hematoxylin
counterstained liver section of indi-
vidual mouse number 1** (106 CTLs
transferred). Note the absence of
red-stained foci. Bar, 50  m. 
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tained long-term in the host (Fig. 1). A critical question is
whether the findings obtained with an in vitro–selected
CTLL also apply to the memory CD8 T cell population
present in the host. To answer this question, an adoptive
transfer experiment was performed with M45-TCR
 
 
 
CD8
 
  
 
ex vivo memory cells sorted by using MHC-Ig hy-
brid molecules loaded with M45 peptide (Fig. 5).
The sorted M45-specific memory cells were highly ef-
ficient in controlling the replication of mutant virus
mCMV-
 
 
 
m152. As few as 2,000 transferred cells gave sig-
nificant protection against liver infection in all recipients
and 10
 
4 
 
cells prevented liver infection in most. It is worth
noting that TCR staining with the dimeric peptide-MHC-
Ig hybrid did not interfere with T cell function in vivo.
This observation contrasts with the experience made previ-
ously with peptide-folded MHC class I tetramers (12).
Despite this remarkable protective capacity of the M45-
specific memory cells, they failed in protecting against pro-
ductive infection with mCMV-
 
 
 
m152-rev. In conclusion,
fully functional M45-specific memory cells are present in the
infected host but cannot protect against a productive infec-
tion by the virus to which they have originally been primed.
Discussion
The M45 peptide represents a highly antigenic epitope
in that it efficiently binds to the presenting MHC class I
molecule, namely Db, primes a quantitatively prominent
acute CD8 T cell response, and induces long-lasting im-
munological memory. According to established terminol-
ogy, one would name it an immunodominant peptide (1).
Currently it is implicit understanding that immunodomi-
nance also means being dominant in contributing to im-
munity. Yet, as we have shown here, the M45 peptide
does not contribute to the control of cytopathogenic
mCMV-WT infection. Hence, it is not involved in immu-
nity that prevents CMV disease. Therefore, we propose to
distinguish between “antigenicity dominance” for epitopes
that elicit a quantitatively prominent response and “immu-
nodominance” for epitopes that contribute significantly to
protective immunity.
Previous work by Gold et al. and LoPiccolo et al. (4, 13)
has shown that the M45 peptide is not presented in cell
culture by infected fibroblasts, macrophages, or a DC line if
immunoevasin m152/gp40 is expressed. In vivo, disease
manifestations of CMV, such as interstitial pneumonia,
hepatitis, adrenalitis, ventriculitis, and gastrointestinal dis-
ease involve a much broader range of cell types (14). The
lack of protection by M45-CTL in vivo indicates that M45
peptide presentation is prevented in the microenvironmen-
tal context of infected tissues and, most importantly, in the
stromal and parenchymal cell types that are relevant to
CMV disease.
This finding was not expected. Although m152/gp40 re-
duced the efficacy of polyclonal antiviral CD8 T cells in the
genetically susceptible BALB/c strain (15), these cells were
still protective against mCMV-WT (16). Accordingly, with
no exception known so far, CTLL specific for dominant as
well as subdominant Kd-, Dd-, and Ld-restricted mCMV
epitopes were found to control infection (10, 11).
M45 is an interesting protein. Its critical role in endothe-
lial cell tropism of mCMV was attributed to an antiapop-
totic function (5). However, any speculation on a link
between inhibition of apoptosis and a selective, M45 pro-
tein-specific immune evasion has to be refuted in view of
the finding that CD8 T cells specific for the subdominant,
Dd-restricted M45 peptide 507-VGPALGRGL-515 (2) pro-
tect against mCMV-WT in the BALB/c model (unpub-
lished data). Rather, as suggested by data on ER retention
(17) and downmodulation of cell surface expression (8), Db
is more susceptible to the effect of m152/gp40 than other
class I allelic products.
The fact that M45-specific CD8 T cells were generated
in high numbers in response to mCMV infection implies
that precursor cells were efficiently primed by professional
APCs presenting the M45 peptide. Notably, the frequen-
cies were found to be about the same in C57BL/6 mice in-
fected with mCMV- m152 and mCMV- m152-rev (4),
which also applies to all known mCMV epitopes in BALB/c
(unpublished data). This finding suggests that immunologi-
cal priming is not influenced by the expression of immuno-
evasin m152/gp40 in infected cells. For an explanation,
Gold et al. (4) discussed the possibility of priming through
uninfected DCs presenting M45 peptide derived by uptake
of the M45 protein from infected cells, a still-debated con-
cept known as cross-presentation (18, 19). Along the same
line, Basta and Bennink (20) recently speculated on cross-
presentation as being an adaptive host response to the viral
inhibition of direct presentation.
The data presented here reveal an important functional
limitation of peptide cross-presentation, at least for CMV
infection. Although cross-presentation may indeed be a
Figure 5. M45-specific memory cells maintain antiviral function but
are unable to prevent productive infection by the priming virus genotype.
M45-TCR  CD8  memory cells were purified by cell sorting from a
pool of spleen cells derived from 15 C57BL/6 mice at 4 mo after infection
with mCMV-WT. The antiviral function was tested by adoptive transfer
into immunocompromised C57BL/6 recipients infected with mutant virus
mCMV- m152 or revertant virus mCMV- m152-rev.  , no cell transfer.
On day 11, virus replication in the liver was quantitated by immunohisto-
logical detection of IE1 protein in the nuclei of infected hepatocytes. Dot
symbols represent data for individual recipients. Median values are marked.Immunodominance of a Nonprotective Viral CD8 T Cell Epitope 136
way to avoid CMV immunoevasins in the priming of an
immune response, the cross-primed effector cells will not
find the respective antigen on infected stromal and paren-
chymal non-APC tissue cells in which immunoevasins are
operative (4). Hence, they will not protect against CMV
disease. This hypothesis is now substantiated.
Our data contribute to a better understanding of CMV
disease. In addition, we see a general importance in the no-
tion that antigenicity dominance and immunodominance
are not necessarily congruous properties of an antigenic
peptide. The choosing of epitopes for use in a vaccine is
largely based on the magnitude of the epitope-specific re-
sponse. Db-M45 is a paradigm for a nonprotective domi-
nant epitope. Our findings underscore the importance of in
vivo protection studies for decision making in vaccine de-
sign and may help to explain, and avoid, vaccine failures.
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